Mahana obtains marketing authorization for IBS digital therapeutic

Parallel, a prescription digital therapeutic developed by Mahana Therapeutics for the treatment of irritable bowel syndrome, received marketing authorization from the FDA, according to a company press release.The 3-month digital program uses cognitive behavioral therapy to help adults change factors that might contribute to IBS.“Parallel provides adult patients suffering from any subtype of IBS with a clinically validated, digitally delivered, cognitive behavioral therapy-based complementary treatment,” Emeran Mayer, MD, a distinguished professor at UCLA, and member of Mahana’sRead More

Share on facebook
Share on twitter
Share on linkedin